STOCK TITAN

SilverBox (SBXD) Reports Parataxis Bridge Bio Deal; Merger Still Pending

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

SilverBox Corp IV (NYSE: SBXD) filed a Form 8-K on June 20, 2025 under Item 7.01 (Regulation FD Disclosure). The filing reiterates that SBXD and Parataxis Holdings LLC signed a non-binding letter of intent on June 9, 2025 regarding a potential business combination. The new disclosure attaches a press release (Exhibit 99.1) issued the same day by Parataxis Holdings announcing a definitive agreement to acquire a controlling interest in Bridge Biotherapeutics, Inc. (KOSDAQ: 288330). Parataxis intends to use this acquisition to establish an institutionally backed Bitcoin treasury company that would be listed on the South Korean public markets.

The 8-K expressly states that the information—including Exhibit 99.1—is being “furnished” rather than “filed”, meaning it is not subject to Section 18 liability and will not be incorporated by reference into SBXD’s Securities Act or Exchange Act filings. No financial statements, pro-forma data, or valuation terms are provided, and SBXD remains in the due-diligence stage: no definitive business-combination agreement has been executed yet.

SBXD advises shareholders that, if a definitive agreement is reached, a newly formed holding company (“PubCo”) together with SBXD and Parataxis Holdings will prepare a registration statement and proxy statement/prospectus, which will be mailed to SBXD shareholders and filed with the SEC. The company directs investors to review those future filings, along with SBXD’s Form 10-K for the year ended December 31, 2024, for detailed risk factors and ownership information.

The filing includes standard forward-looking-statement disclaimers highlighting risks such as potential termination of negotiations, regulatory approvals, listing uncertainties, and market demand for digital assets in South Korea. It also clarifies that the 8-K does not constitute an offer or solicitation related to any securities.

Key take-away for investors: The disclosure signals incremental progress toward a possible SPAC merger, but material deal terms, financial impacts, and closing conditions remain unknown. Until a binding agreement is signed and a registration statement is filed, SBXD’s transaction timeline and economics are speculative.

Positive

  • Progress signal: Parataxis Holdings has entered a definitive agreement related to its strategy, indicating momentum toward SBXD’s contemplated business combination.

Negative

  • Non-binding status: SBXD still lacks a definitive merger agreement; all transaction terms and timelines remain uncertain.
  • No financial disclosure: The 8-K provides no valuation, pro-forma financials, or capital-structure details, limiting investor visibility.

Insights

TL;DR: Filing shows progress toward a deal but remains non-binding; impact neutral pending definitive merger terms.

The 8-K furnishes a press release from Parataxis Holdings about acquiring Bridge Biotherapeutics to create a Bitcoin treasury vehicle. This indirectly supports SBXD’s previously announced LOI, suggesting the target is executing preparatory strategic moves. However, SBXD still lacks a signed merger agreement, valuation metrics, or a timetable. Because the disclosure is furnished, it carries limited legal weight and no financial statements. For SPAC investors, the news incrementally de-risks target readiness but does not yet crystallize deal economics or redemption considerations. Accordingly, market impact should be modest until a definitive business-combination agreement and proxy are released.

TL;DR: Material uncertainties remain; forward-looking risks outweigh near-term benefits—overall neutral.

While Parataxis’s definitive purchase of Bridge Biotherapeutics demonstrates momentum, numerous contingencies persist: shareholder approval, exchange listing of PubCo, regulatory reviews, and digital-asset market volatility in South Korea. The filing’s extensive risk disclosure underscores the possibility of deal collapse or material term changes. Because no financial commitments are yet disclosed, investors cannot assess dilution, valuation, or pro-forma leverage. Therefore, the event neither materially improves nor degrades SBXD’s risk profile at this stage.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
false 0002015947 00-0000000 0002015947 2025-06-20 2025-06-20 0002015947 SBXD:UnitsEachConsistingOfOneClassaOrdinaryShare0.0001ParValueAndOnethirdOfOneRedeemableWarrantMember 2025-06-20 2025-06-20 0002015947 SBXD:ClassaOrdinarySharesIncludedAsPartOfUnitsMember 2025-06-20 2025-06-20 0002015947 SBXD:RedeemableWarrantsIncludedAsPartOfUnitsEachWholeWarrantExercisableForOneClassaOrdinaryShareAtExercisePriceOf11.50Member 2025-06-20 2025-06-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

Current Report

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 20, 2025

 

SilverBox Corp IV

(Exact Name of Registrant as Specified in Its Charter)

 

Cayman Islands   001-42214   N/A
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

1250 S. Capital of Texas Highway,
Building 2, Suite 285

Austin
, TX
  78746
(Address of Principal Executive Offices)   (Zip Code)

 

(512) 575-3637  
  (Registrant’s Telephone Number, Including Area Code)  

 

  N/A  
  (Former Name or Former Address, if Changed Since
Last Report)
 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each exchange
on which registered
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-third of one redeemable warrant   SBXD.U   New York Stock Exchange LLC
Class A ordinary shares included as part of the units   SBXD   New York Stock Exchange LLC
Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50   SBXD WS   New York Stock Exchange LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

As previously announced on June 9, 2025, SilverBox Corp IV (“SBXD”) and Parataxis Holdings LLC (“Parataxis Holdings”) entered into a non-binding letter of intent for a potential business combination. On June 20, 2025, Parataxis Holdings issued a press release announcing a definitive agreement to acquire a controlling interest in Bridge Biotherapeutics, Inc., a Korean company listed on the KOSDAQ. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

In addition, the following is a LinkedIn post by Joseph E. Reece, Founder Partner of SBXD:

 

Parataxis Holdings announces definitive agreement to establish a Bitcoin treasury company in South Korea

 

Read the press release of Parataxis Holdings here: Parataxis Holdings LLC Announces Definitive Agreement with Bridge Biotherapeutics, Inc. (KOSDAQ: 288330), to Bring Institutionally-Backed, Bitcoin Treasury Company to the South Korean Public Markets.

 

The information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the filings of SBXD under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.   Description
99.1   Press Release of Parataxis Holdings dated June 20, 2025
104   Cover Page Interactive Data File (embedded within the inline XBRL Document)

 

Additional Information and Where to Find It

 

If a definitive agreement is entered into in connection with the proposed business combination, a newly formed holding company (“PubCo”), SBXD and Parataxis Holdings will prepare and file a registration statement, including a proxy statement/prospectus of SBXD and PubCo, to be filed with the U.S. Securities and Exchange Commission (“SEC”). The proxy statement/prospectus will be mailed to SBXD’s shareholders. SBXD urges investors and other interested persons to read, when available, the proxy statement/prospectus, as well as other documents filed with the SEC, because these documents will contain important information about the proposed business combination. Such persons can also read SBXD’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “SBXD Annual Report”), for a description of the security holdings of its officers and directors and their respective interests as security holders in the consummation of the proposed business combination. The proxy statement statement/prospectus, once available, and the SBXD Annual Report can be obtained, without charge, at the SEC’s web site (http://www.sec.gov).

 

Participants in the Solicitation

 

Parataxis Holdings, SBXD and PubCo and their respective directors, executive officers and other members of their management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of SBXD’s shareholders in connection with the proposed business combination. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of SBXD’s directors and officers in SBXD’s Annual Report. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to SBXD’s shareholders in connection with the proposed business combination will be set forth in the proxy statement/prospectus for the proposed business combination when available. Information concerning the interests of Parataxis Holdings’, SBXD’s and PubCo’s participants in the solicitation, which may, in some cases, be different than those of their respective equityholders generally, will be set forth in the proxy statement/prospectus relating to the proposed business combination when it becomes available.

 

 

 

 

Forward-Looking Statements

 

This Current Report on Form 8-K includes “forward-looking statements” with respect to SBXD and Parataxis Holdings within the meaning of the federal securities laws. The expectations, estimates, and projections of the businesses of Parataxis Holdings and SBXD may differ from their actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to execution of a definitive agreement with respect to the proposed business combination, future performance and anticipated financial impacts of the proposed business combination, the satisfaction of the closing conditions to the proposed business combination, and the timing of the completion of the proposed business combination. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of Parataxis Holdings and SBXD and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the negotiations and any subsequent definitive agreements with respect to the proposed business combination, and the possibility that the terms and conditions set forth in any definitive agreements with respect to the proposed business combination may differ materially from the terms and conditions set forth in the term sheet; (2) the outcome of any legal proceedings that may be instituted against the parties following the announcement of the proposed business combination and any definitive agreements with respect thereto; (3) the inability to complete the proposed business combination and the related transactions, including due to failure to obtain approval of the shareholders of SBXD or other conditions to closing; (4) the inability to obtain or maintain the listing of PubCo’s common equity on a stock exchange following the proposed business combination; (5) the risk that the proposed business combination disrupts current plans and operations as a result of the announcement and consummation of the proposed business combination; (6) the ability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition, the ability of PubCo to grow and manage growth profitably and retain its key employees, and the demand in South Korea for digital assets; (7) costs related to the proposed business combination; (8) changes in applicable laws or regulations; and (9) other risks and uncertainties included in (x) the “Risk Factors” sections of the SBXD Annual Report and (y) other documents filed or to be filed with or furnished or to be furnished to the SEC by Parataxis Holdings, PubCo and SBXD. The foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. Parataxis Holdings and SBXD do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Past performance by Parataxis Holdings’ or SBXD’s management teams and their respective affiliates is not a guarantee of future performance. Therefore, you should not place undue reliance on the historical record of the performance of Parataxis Holdings’ or SBXD’s management teams or businesses associated with them as indicative of future performance of an investment or the returns that Parataxis Holdings or SBXD will, or are likely to, generate going forward.

 

No Offer or Solicitation

 

This Current Report on Form 8-K shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This Current Report on Form 8-K shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SILVERBOX CORP IV
   
Date: June 20, 2025 By: /s/ Jin Chun
     
    Jin Chun
    Chief Operating Officer

 

 

 

FAQ

What did SilverBox Corp IV (SBXD) disclose in its June 20, 2025 Form 8-K?

SBXD furnished a Parataxis Holdings press release outlining a definitive agreement to buy Bridge Biotherapeutics and reiterated its non-binding LOI with Parataxis.

Is the SBXD–Parataxis business combination definitive?

No. The parties have only a non-binding letter of intent; no definitive merger agreement has been executed.

Does the 8-K include any financial terms or valuation of the proposed transaction?

No. The filing contains no financial statements, valuations, or pro-forma data related to the potential merger.

Will shareholders get a vote on the potential SBXD business combination?

Yes. If a definitive agreement is reached, a proxy statement/prospectus will be mailed to SBXD shareholders for voting.

Why is the information marked as "furnished" rather than "filed"?

Item 7.01 disclosures are furnished, meaning they are not subject to Section 18 liability and are not automatically incorporated into other SEC filings.